Lori Rudolph-Owen

Lori Rudolph-Owen joined Goldfinch in 2018 as Senior Vice President of R&D Strategy and Operation and has served as CDO since early 2020. Lori brings over 20 years of leadership experience in pharmaceutical and biotechnology R&D, specifically in strategic portfolio planning and leadership, development operations and building talent for optimal organization growth. Lori’s prior responsibilities include driving multiple INDs and proof of concept studies, CMC Quality improvements and expansion indications for FERAHEME, global registration studies for DACOGEN, and line function responsibilities for US and EU submissions, approvals and launches of VARUBI/VARUBY and ZEJULA.

Prior to joining Goldfinch, Lori served at the Vice President of Portfolio Management and Assessment at TESARO, Inc, and held positions of increasing leadership responsibility at Pfizer, AMAG Pharmaceuticals, MGI Pharma (now Eisai), and Vertex.

Dr. Rudolph-Owen received her PhD in Cell Biology at Vanderbilt University. After completing a postdoctoral fellowship, she joined Millennium Pharmaceuticals as an Oncology Discovery Scientist before transitioning to Drug Development Program Leadership at Vertex.